These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18723346)

  • 1. Discovery of amido-benzisoxazoles as potent c-Kit inhibitors.
    Kunz RK; Rumfelt S; Chen N; Zhang D; Tasker AS; Bürli R; Hungate R; Yu V; Nguyen Y; Whittington DA; Meagher KL; Plant M; Tudor Y; Schrag M; Xu Y; Ng GY; Hu E
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5115-7. PubMed ID: 18723346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit.
    Hu E; Tasker A; White RD; Kunz RK; Human J; Chen N; Bürli R; Hungate R; Novak P; Itano A; Zhang X; Yu V; Nguyen Y; Tudor Y; Plant M; Flynn S; Xu Y; Meagher KL; Whittington DA; Ng GY
    J Med Chem; 2008 Jun; 51(11):3065-8. PubMed ID: 18447379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
    Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
    Deak HL; Newcomb JR; Nunes JJ; Boucher C; Cheng AC; DiMauro EF; Epstein LF; Gallant P; Hodous BL; Huang X; Lee JH; Patel VF; Schneider S; Turci SM; Zhu X
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1172-6. PubMed ID: 18083554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
    Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling.
    Tong Y; Stewart KD; Thomas S; Przytulinska M; Johnson EF; Klinghofer V; Leverson J; McCall O; Soni NB; Luo Y; Lin NH; Sowin TJ; Giranda VL; Penning TD
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5206-8. PubMed ID: 18790640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biology of Kit in disease and the application of pharmacogenetics.
    Akin C; Metcalfe DD
    J Allergy Clin Immunol; 2004 Jul; 114(1):13-9; quiz 20. PubMed ID: 15241338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors.
    Hanan EJ; Fucini RV; Romanowski MJ; Elling RA; Lew W; Purkey HE; VanderPorten EC; Yang W
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5186-9. PubMed ID: 18790636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3.
    Angell RM; Atkinson FL; Brown MJ; Chuang TT; Christopher JA; Cichy-Knight M; Dunn AK; Hightower KE; Malkakorpi S; Musgrave JR; Neu M; Rowland P; Shea RL; Smith JL; Somers DO; Thomas SA; Thompson G; Wang R
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1296-301. PubMed ID: 17194588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computer simulations reveal a novel nucleotide-type binding orientation for ellipticine-based anticancer c-kit kinase inhibitors.
    Thompson D; Miller C; McCarthy FO
    Biochemistry; 2008 Sep; 47(39):10333-44. PubMed ID: 18754682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.
    Leftheris K; Ahmed G; Chan R; Dyckman AJ; Hussain Z; Ho K; Hynes J; Letourneau J; Li W; Lin S; Metzger A; Moriarty KJ; Riviello C; Shimshock Y; Wen J; Wityak J; Wrobleski ST; Wu H; Wu J; Desai M; Gillooly KM; Lin TH; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Zhang R; Diller D; Doweyko A; Sack J; Baldwin J; Barrish J; Dodd J; Henderson I; Kanner S; Schieven GL; Webb M
    J Med Chem; 2004 Dec; 47(25):6283-91. PubMed ID: 15566298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
    Wang H; Ruan Z; Li JJ; Simpkins LM; Smirk RA; Wu SC; Hutchins RD; Nirschl DS; Van Kirk K; Cooper CB; Sutton JC; Ma Z; Golla R; Seethala R; Salyan ME; Nayeem A; Krystek SR; Sheriff S; Camac DM; Morin PE; Carpenter B; Robl JA; Zahler R; Gordon DA; Hamann LG
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3168-72. PubMed ID: 18485702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.
    Angell RM; Angell TD; Bamborough P; Brown D; Brown M; Buckton JB; Cockerill SG; Edwards CD; Jones KL; Longstaff T; Smee PA; Smith KJ; Somers DO; Walker AL; Willson M
    Bioorg Med Chem Lett; 2008 Jan; 18(1):324-8. PubMed ID: 17981461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process.
    Zou J; Wang YD; Ma FX; Xiang ML; Shi B; Wei YQ; Yang SY
    Proteins; 2008 Jul; 72(1):323-32. PubMed ID: 18214972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinase array design, back to front: biaryl amides.
    Baldwin I; Bamborough P; Haslam CG; Hunjan SS; Longstaff T; Mooney CJ; Patel S; Quinn J; Somers DO
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5285-9. PubMed ID: 18789685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors.
    Zhao H; Liu G; Xin Z; Serby MD; Pei Z; Szczepankiewicz BG; Hajduk PJ; Abad-Zapatero C; Hutchins CW; Lubben TH; Ballaron SJ; Haasch DL; Kaszubska W; Rondinone CM; Trevillyan JM; Jirousek MR
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5543-6. PubMed ID: 15482920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of KIT receptor tyrosine kinase protein in normal human skin: preliminary observations.
    Hussein MR
    Cell Biol Int; 2007 Jul; 31(7):748-51. PubMed ID: 17337216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.